Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus SHEUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus SHEUR.
IMPOYZ vs SHEUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
SHEUR is a small molecule inhibitor of the bromodomain and extraterminal (BET) family proteins, specifically BRD2, BRD3, BRD4, and BRDT. By binding to acetyl-lysine recognition motifs, it disrupts chromatin remodeling and transcriptional regulation, leading to reduced expression of oncogenes such as MYC.
100 mg orally twice daily
No standard dosing available; SHEUR is not a recognized pharmaceutical agent.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 4.5 hours; clinically, steady-state reached within 24 hours.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Renal: 70% unchanged; Biliary/Fecal: 30% as metabolites.
Category C
Category C
Unknown
Unknown